Structure-Guided Covalent Design and Biological Evaluation of Glycidamido-Leucinamide Antivirulence Agents Against Pseudomonas aeruginosa
Open Access
- 23 September 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8465
Abstract
Antimicrobial resistance in Pseudomonas aeruginosa has intensified the need for therapies that do not rely solely on bactericidal activity. Antivirulence agents attenuate pathogenic functions and may complement conventional antibiotics. The elastase LasB is a major quorum-sensing (QS)-controlled virulence factor of P. aeruginosa. Starting from the validated N-aryl/α-isobutyl recognition motif of LasB inhibitors, we used an integrated computational workflow combining chemical-space mapping of known LasB inhibitors, focused covalent-library enumeration, and Glu141-directed covalent docking to design glycidamide analogues bearing an epoxide-containing motif. Two compounds were synthesised and characterised, QSI-1 (4-(trifluoromethyl)phenyl) and QSI-2 (4-fluorophenyl), forming a matched molecular pair that differs only at the para substituent. Both compounds inhibited biofilm formation at sub-micromolar concentrations (QSI-1, IC50 = 0.28 μM; QSI-2, IC50 = 0.51 μM) and directly inhibited purified recombinant LasB, with IC50 values of 2.98 μM and 10.20 μM, respectively. Both also preferentially reduced lasB promoter activity relative to the rhlA and pqsA reporters. QSI-1, selected for further evaluation, reduced virulence-factor production and surface-associated motility without measurably inhibiting bacterial growth. QSI-1 enhanced the activity of azithromycin in vitro, and the combination of QSI-1 (25 μM) with azithromycin (0.05 μg/mL) accelerated wound closure and reduced bacterial burden in a murine excisional wound-infection model. QSI-1 showed low cytotoxicity toward mammalian cells at concentrations up to 200 μM. These findings identify QSI-1 and QSI-2 as covalently designed LasB-active antivirulence leads, while direct experimental confirmation of Glu141 covalent modification remains to be established.Keywords
Funding Information
- Guangzhou Basic and Applied Basic Research Foundation–Science and Technology Elite “Piloting” Project (2024A04J6491)
- National Natural Science Foundation of China (82574239)
- Tianchi Academic Elite Leader Project (2025A1515010145)
- Guangdong Basic and Applied Basic Research Foundation (2026A1515010127)
This publication has 37 references indexed in Scilit:
- Machine learning-driven discovery of aniline phenylacetate derivatives as LasR-targeted biofilm inhibitors against Pseudomonas aeruginosa infectionsActa Pharmaceutica Sinica B, 2026
- Dipeptidic Phosphonates: Potent Inhibitors of Pseudomonas aeruginosa Elastase B Showing Efficacy in a Murine Keratitis ModelAdvanced Science, 2025
- Unleashing the future: The revolutionary role of machine learning and artificial intelligence in drug discoveryEuropean Journal of Pharmacology, 2024
- Inhibition of biofilm formation, quorum sensing and virulence factor production in Pseudomonas aeruginosa PAO1 by selected LasR inhibitorsInternational Microbiology, 2023
- Pseudomonas aeruginosa elastase (LasB) as a therapeutic targetDrug Discovery Today, 2021
- Structural and Biochemical Studies of Non-native Agonists of the LasR Quorum-Sensing Receptor Reveal an L3 Loop “Out” Conformation for LasRCell Chemical Biology, 2018
- Disarming Pseudomonas aeruginosa Virulence Factor LasB by Leveraging a Caenorhabditis elegans Infection ModelChemistry & Biology, 2015
- Drug discovery considerations in the development of covalent inhibitorsBioorganic & Medicinal Chemistry Letters, 2014
- Antibiotic resistance of bacterial biofilmsInternational Journal of Antimicrobial Agents, 2010
- Molecular Basis for the Recognition of Structurally Distinct Autoinducer Mimics by the Pseudomonas aeruginosa LasR Quorum-Sensing Signaling ReceptorChemistry & Biology, 2009